Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDP Indaptus Therapeutics, Inc.

Closed 10-31 16:00:00 EDT

1.17

-0.07

-5.65%

盘后1.17

+0.000.00%

16:45 EDT

High1.25	Low1.13	Vol48.57K
Open1.25	D1 Closing1.24	Amplitude9.31%
Mkt Cap11.93M	Tradable Cap8.75M	Total Shares10.20M
T/O57.10K	T/O Rate0.65%	Tradable Shares7.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"INDP","market":"US","secType":"STK","nameCN":"Indaptus Therapeutics, Inc.","latestPrice":1.17,"timestamp":1730404800000,"preClose":1.24,"halted":0,"volume":48571,"hourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.17,"latestTime":"16:45 EDT","volume":47,"amount":58.7499,"timestamp":1730407504164},"delay":0,"floatShares":7477001,"shares":10196884,"eps":-1.864176,"marketStatus":"Closed","change":-0.07,"latestTime":"10-31 16:00:00 EDT","open":1.25,"high":1.25,"low":1.1346,"amount":57103.5641,"amplitude":0.093065,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.864176,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730448000000},"marketStatusCode":5,"adr":0,"listingDate":1438660800000,"exchange":"NASDAQ","adjPreClose":1.24,"preHourTrading":{"tag":"盘前","latestPrice":1.3499,"preClose":1.24,"latestTime":"08:30 EDT","volume":1,"amount":1.3499,"timestamp":1730377849181},"postHourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.17,"latestTime":"16:45 EDT","volume":47,"amount":58.7499,"timestamp":1730407504164},"volumeRatio":0.380452},"requestUrl":"/m/hq/s/INDP/wiki","defaultTab":"wiki","newsList":[{"id":"2477262369","title":"Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2477262369","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477262369?lang=en_us&edition=fundamental","pubTime":"2024-10-23 02:24","pubTimestamp":1729621440,"startTime":"0","endTime":"0","summary":"Shares of Indaptus Therapeutics rose after the company said it reached an agreement with BeiGene to evaluate novel cancer treatment combinations.The stock gained 14% to $1.68 in afternoon trading Tuesday. Shares are down 6.8% since the beginning of the year.Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied as a treatment for various cancers, such as liver, colon and pancreatic -- in combination with BeiGene's anti-PD-1 antibody, called tislelizumab.Preclinical studies showed that Decoy20, when used in combination with a PD-1 inhibitor and an oral non-steroidal anti-inflammatory agent, demonstrated tumor eradication rates of between 80% and 100%, Indaptus said.Terms of the agreement weren't disclosed. As part of the pact, BeiGene will provide Indaptus with access to its PD-1 inhibitor, as well as provide technical expertise to accelerate t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4505","BK4585","06160","BK4504","LU0307460666.USD","BK4526","INDP","LU1969619763.USD","BK4588","BK1161","LU0588546209.SGD","BK1500","BK1588","BK4535","BK4139","LU2328871848.SGD","BK4548","BGNE","BK1583"],"gpt_icon":0},{"id":"2477836651","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2477836651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477836651?lang=en_us&edition=fundamental","pubTime":"2024-10-23 01:52","pubTimestamp":1729619568,"startTime":"0","endTime":"0","summary":"Mueller Industries (MLI) reported a year-over-year increase in fiscal Q3 adjusted diluted earnings and net sales late Monday.Shares jumped 16%, with intraday trading volume at over 1.17 million compar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0477156953.USD","BK4505","LU0130518102.USD","LU0130102774.USD","LU0211331839.USD","MLI","BK4574","BK4555","BK4559","BK4516","BGNE","LU0208291251.USD","LU0345770308.USD","INDP","LU0320765489.SGD","LU0130517989.USD","BK4504","BK4588","BK4526","LU0345770993.USD","LU0070302665.USD","BK4585","LU0130103400.USD","LU1201861249.SGD","LU1201861165.SGD","LU0162691827.USD","LU0648000940.SGD","LU0648001328.SGD","BK4566","LU0980610538.SGD","BK4139","BK4099","BK4548","GM","LU0477156797.USD","BK4161","BK4535","BK4561","LU0072461881.USD","LU0006061336.USD"],"gpt_icon":0},{"id":"2477583343","title":"Indaptus Therapeutics signs clinical supply agreement with Beigene","url":"https://stock-news.laohu8.com/highlight/detail?id=2477583343","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477583343?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:34","pubTimestamp":1729604059,"startTime":"0","endTime":"0","summary":"Eoneren/E+ via Getty Images  Indaptus Therapeutics  announced a clinical supply agreement with BeiGene  . Indaptus plans to advance human clinical evaluation of the combination of BeiGene's anti-PD-1 antibody, tislelizumab, with Indaptus’ Decoy20, a novel treatment designed to induce a broad immune response to fight cancer.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4189766-indaptus-therapeutics-signs-clinical-supply-agreement-with-beigene","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4139","LENZ","06160","LU1969619763.USD","BK4588","INDP","BK1588","LU2328871848.SGD",".IXIC","NQmain","LU0307460666.USD","BGNE","PSQ","TQQQ","BK1500","SQQQ","LU0588546209.SGD","QLD","BK4548","BK4504","MNQmain","BK4505","BK1161","QID","BK1583","BK4585","BK4526","BK4535"],"gpt_icon":0},{"id":"2477228336","title":"BRIEF-Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene To Evaluate Novel Cancer Treatment Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477228336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477228336?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:40","pubTimestamp":1729600830,"startTime":"0","endTime":"0","summary":"Oct 22  - Indaptus Therapeutics Inc   :   * INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS   * INDAPTUS THERAPEUTICS INC - INDUSTRY FIRST CLINICAL TRIAL COMBINING TISLELIZUMAB AND DECOY20 EXPECTED  TO START IN 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BGNE","INDP"],"gpt_icon":0},{"id":"2477338722","title":"Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene to Evaluate Novel Cancer Treatment Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477338722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477338722?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUABHJV7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2477338083","title":"Indaptus Therapeutics Inc - Industry First Clinical Trial Combining Tislelizumab and Decoy20 Expected  to Start in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2477338083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477338083?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUABHJV7S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2475966736","title":"Indaptus Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2475966736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475966736?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:15","pubTimestamp":1729077300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INDP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2024 07:15 ET (11:15 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","INDP"],"gpt_icon":0},{"id":"2475920508","title":"Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2475920508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475920508?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUACFST5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2467153791","title":"Indaptus Therapeutics files to sell 1.64M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2467153791","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467153791?lang=en_us&edition=fundamental","pubTime":"2024-09-13 12:53","pubTimestamp":1726203220,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics (NASDAQ:INDP) filed a prospectus related to the offer and resale by the selling stockholders of up to 1,643,837 shares of common stock.\nThe warrants were issued and sold to accredited investors in a private placement  which closed on August 8, 2024.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346675513/image_1346675513.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346675513/image_1346675513.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4149312-indaptus-therapeutics-files-to-sell-164m-shares-of-common-stock-for-holders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["INDP","SQQQ","TQQQ","PSQ","LENZ",".IXIC","NQmain","BK4139","QID","MNQmain","QLD"],"gpt_icon":1},{"id":"2465546889","title":"Indaptus Therapeutics Inc: Initiate Dosing Patients at Higher Decoy20 Dose on a Weekly Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2465546889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465546889?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2465450265","title":"Indaptus Therapeutics Inc: Safety Profile Being Observed to Date Continues to Be Consistent With Decoy20's Mechanism of Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2465450265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465450265?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2465154576","title":"Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2465154576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465154576?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2465012545","title":"Indaptus Therapeutics Inc: Continue Dosing Additional Patients at Lower Decoy20 Dose on a Weekly Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2465012545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465012545?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2458879602","title":"Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2458879602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458879602?lang=en_us&edition=fundamental","pubTime":"2024-08-12 20:00","pubTimestamp":1723464003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nTUABRVB3V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LENZ","INDP"],"gpt_icon":0},{"id":"2458024496","title":"Indaptus Therapeutics  - Expects Current Cash and Cash Equivalents Will Support Ongoing Operating Activities Into Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2458024496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458024496?lang=en_us&edition=fundamental","pubTime":"2024-08-12 20:00","pubTimestamp":1723464003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nTUABRVB3V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139","LENZ"],"gpt_icon":0},{"id":"2458604040","title":"Indaptus Therapeutics Q2 EPS USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2458604040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458604040?lang=en_us&edition=fundamental","pubTime":"2024-08-12 20:00","pubTimestamp":1723464002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nPLXA7FAFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["USD","INDP","BK4139","LENZ"],"gpt_icon":0},{"id":"2458269196","title":"Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m","url":"https://stock-news.laohu8.com/highlight/detail?id=2458269196","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458269196?lang=en_us&edition=fundamental","pubTime":"2024-08-11 22:05","pubTimestamp":1723385136,"startTime":"0","endTime":"0","summary":"Insiders who bought US$216.4k worth of Indaptus Therapeutics, Inc.'s  stock at an average buy price of US$2.09 over the last year may be disappointed by the recent 10% decrease in the stock. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$175.7k, which is not great.While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.The Last 12 Months Of Insider Transactions At Indaptus Therapeutics. But note: Indaptus Therapeutics may not be the best stock to buy.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buyers-lose-us-41k-140536631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INDP","LENZ","BK4139"],"gpt_icon":0},{"id":"2457194238","title":"Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2457194238","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457194238?lang=en_us&edition=fundamental","pubTime":"2024-08-07 19:00","pubTimestamp":1723028400,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug. 07, 2024  -- Indaptus Therapeutics, Inc.  , a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,643,837 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,643,837 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.825. The warrants will have an exercise price of $1.70 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about August 8, 2024, subject to the satisfaction of customary closing conditions.This press release shall not consti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3XXQS3YWdGJ1JC2JJgEReg--~B/aD02MDt3PTIyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3XXQS3YWdGJ1JC2JJgEReg--~B/aD02MDt3PTIyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-inc-announces-3-110000700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2444115093","title":"Indaptus Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2444115093","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444115093?lang=en_us&edition=fundamental","pubTime":"2024-06-17 18:50","pubTimestamp":1718621400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INDP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2024 06:50 ET (10:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","LENZ"],"gpt_icon":0},{"id":"2441195250","title":"Indaptus Therapeutics Elects Directors and Approves Key Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2441195250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441195250?lang=en_us&edition=fundamental","pubTime":"2024-06-08 05:14","pubTimestamp":1717794863,"startTime":"0","endTime":"0","summary":"An announcement from Indaptus Therapeutics (INDP) is now available. During the Company’s Annual Meeting on June 6, 2024, with over 50% of outstandi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/indaptus-therapeutics-elects-directors-and-approves-key-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/indaptus-therapeutics-elects-directors-and-approves-key-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","INDP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indaptusrx.com","stockEarnings":[{"period":"1week","weight":-0.2663},{"period":"1month","weight":0},{"period":"3month","weight":-0.3951},{"period":"6month","weight":-0.3861},{"period":"1year","weight":-0.4655},{"period":"ytd","weight":-0.2955}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.0108},{"period":"3month","weight":0.068},{"period":"6month","weight":0.1342},{"period":"1year","weight":0.3867},{"period":"ytd","weight":0.2201}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.027434},{"month":2,"riseRate":0.444444,"avgChangeRate":0.014519},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.025686},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016408},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.032542},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.014205},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.050227},{"month":8,"riseRate":0.444444,"avgChangeRate":0.063432},{"month":9,"riseRate":0.4,"avgChangeRate":-0.005204},{"month":10,"riseRate":0.2,"avgChangeRate":-0.106163},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.021385},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.047011}],"exchange":"NASDAQ","name":"Indaptus Therapeutics, Inc.","nameEN":"Indaptus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Indaptus Therapeutics, Inc.,INDP,Indaptus Therapeutics, Inc.股票,Indaptus Therapeutics, Inc.股票老虎,Indaptus Therapeutics, Inc.股票老虎国际,Indaptus Therapeutics, Inc.行情,Indaptus Therapeutics, Inc.股票行情,Indaptus Therapeutics, Inc.股价,Indaptus Therapeutics, Inc.股市,Indaptus Therapeutics, Inc.股票价格,Indaptus Therapeutics, Inc.股票交易,Indaptus Therapeutics, Inc.股票购买,Indaptus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction